The resulting formulation was resistant to acidic in vitro conditions mimicking those in the stomach, and the prodrug was able to enter MDA-MB-231 breast cancer cells, with uptake reduced by the addition of sodium taurocholate, indicating the involvement of ASBT/SLC10A2 [185]. The gene discussed is SLC10A2; the disease is breast carcinoma.